181 related articles for article (PubMed ID: 11187723)
1. [Guideline for the treatment of Hansen's disease in Japan].
Goto M; Ishida Y; Gidoh M; Nagao E; Namisato M; Ishii N; Ozaki M;
Nihon Hansenbyo Gakkai Zasshi; 2000 Nov; 69(3):157-77. PubMed ID: 11187723
[TBL] [Abstract][Full Text] [Related]
2. [Guideline for the treatment of Hansen's disease in Japan (Second edition)].
Goto M; Nogami R; Hatano K; Okano Y; Ishii N; Gidoh M; Ishida Y; Ozaki M;
Nihon Hansenbyo Gakkai Zasshi; 2006 Sep; 75(3):191-226. PubMed ID: 17037376
[TBL] [Abstract][Full Text] [Related]
3. [Guidelines for the treatment of Hansen's disease in Japan (third edition)].
Goto M; Nogam R; Okano Y; Gidoh M; Yotsu R; Ishida Y; Kitajima S; Kai M; Ishii N; Ozaki M; Hatano K; ;
Nihon Hansenbyo Gakkai Zasshi; 2013 Dec; 82(3):143-84. PubMed ID: 24579462
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy of leprosy: theoretical basis of new guideline in Japan].
Goto M
Nihon Hansenbyo Gakkai Zasshi; 2001 Aug; 70(3):151-5. PubMed ID: 11579514
[TBL] [Abstract][Full Text] [Related]
5. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
7. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
9. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
10. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
11. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
12. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment.
Prasad PV; Babu A; Kaviarasan PK; Viswanathan P; Tippoo R
Indian J Dermatol Venereol Leprol; 2005; 71(4):242-5. PubMed ID: 16394431
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
15. The new challenges for chemotherapy research.
Grosset J
Lepr Rev; 2000 Dec; 71 Suppl():S100-4. PubMed ID: 11201863
[TBL] [Abstract][Full Text] [Related]
16. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
17. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
18. Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
Chopra NK; Agarwal JS; Pandya PG
Indian J Lepr; 1989 Apr; 61(2):179-89. PubMed ID: 2746026
[TBL] [Abstract][Full Text] [Related]
19. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
20. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
